Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target
Spruce Biosciences, Inc SPRB
$48.72
▼ -0.61%
($-0.30)
🎈 Low Float
🎢 High Beta
Open
$49.22
Prev Close
$49.02
Day Range
$47.54 – $49.31
52W Range
$7.26 – $240.00
Market Cap
$140.02M
Beta
3.71
EPS (TTM)
$-38.31
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-09 |
| Shares Out. | 2,750,000 |
| Website | sprucebio.com/ ↗ |
| Phone | 13026365400 |
| Employees | 8 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$16.2M |
| Free Cash Flow | -$42.8M |
| Total Assets | $102.9M |
| Total Liabilities | $19.1M |
| Equity | $83.7M |
About Spruce Biosciences, Inc
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
Spruce Biosciences, Inc is a publicly traded company under the ticker symbol SPRB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-09-01)